TNF and infection: The incidence of overall AEs, overall infections, and URTIs appeared to be more frequent with TNF inhibitors etanercept (64, 47, and 17% respectively), adalimumab 0.4 mg/kg (77, 56, and 10%, respectively) and adalimumab 0.8 mg/kg (68, 45, and 5%, respectively) than with the IL-12/23 ustekinumab 0.375 mg/kg (51, 32, and 3%, respectively) or ustekinumab 0.75 mg/kg (44, 22, and 8%, respectively) (Figure 4).